Molecular Partners: Positive Phase 1 Data at ASCO

 

• Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment
• Favorable and manageable safety profile observed at all tested dose levels
• Weekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamics
• Data support further clinical evaluation of MP0317 in combination settings

https://www.globenewswire.com/news-release/2024/06/01/2891809/0/en/Molecular-Partners-Presents-Positive-Data-From-Completed-Phase-1-Trial-Of-MP0317-FAP-X-CD40-DARPin-Monotherapy-In-Patients-With-Advanced-Solid-Tumors-At-ASCO-2024.html